NEXT

Noven’s DOT Matrix® transdermal technologies have proven their value in the marketplace. Today, several market-leading or innovative new products incorporate our transdermal technologies, giving these products unique qualities that distinguish them in highly competitive markets.

•
 Three hormone therapy (HT) patches: Vivelle-Dot® (the world's smallest estrogen patch and the most dispensed estrogen patch in the U.S.); original Vivelle®(predecessor to Vivelle-Dot®, now discontinued); and CombiPatch® (the first FDA approved combination HT patch).
•

The first patch for Attention Deficit Hyperactivity Disorder: Daytrana®

These products stand out in the marketplace because Noven's technology endows them with important qualities: consistent dosing, efficient drug delivery, small patch size, extended wear, comfort, and excellent adhesion. As it has done for these products, Noven’s technology can give your product significant benefits over traditional delivery methods and potentially extend patent protection.

For additional information, contact Noven Business Development.

Copyright © 2012 Noven Pharmaceuticals, Inc. All rights reserved.